Transgene SA (OTCMKTS:TRGNF) Sees Significant Drop in Short Interest

Transgene SA (OTCMKTS:TRGNF) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 5 shares, a drop of 99.7% from the July 15th total of 1,507 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Transgene Price Performance

TRGNF opened at $0.85 on Thursday. The company has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $0.92. Transgene has a 52 week low of $0.85 and a 52 week high of $1.08.

About Transgene

Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.

The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity.